Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $32.00 at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA - Free Report) had its price target raised by HC Wainwright from $30.00 to $32.00 in a research note released on Monday, Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also issued reports on TYRA. Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and upped their target price for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Piper Sandler began coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an "overweight" rating and a $33.00 price target on the stock. Wedbush reissued an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday. Finally, Oppenheimer boosted their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research report on Thursday, September 19th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences currently has an average rating of "Buy" and a consensus target price of $31.40.

Tyra Biosciences Price Performance

NASDAQ TYRA traded down $2.04 on Monday, hitting $19.89. The company had a trading volume of 1,199,634 shares, compared to its average volume of 171,076. The company has a market capitalization of $1.05 billion, a PE ratio of -11.77 and a beta of 1.01. The company's fifty day moving average price is $22.89 and its 200-day moving average price is $19.87. Tyra Biosciences has a 12-month low of $10.60 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. On average, sell-side analysts anticipate that Tyra Biosciences will post -1.53 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, CEO Todd Harris sold 19,084 shares of the company's stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $27.90, for a total value of $532,443.60. Following the transaction, the chief executive officer now owns 1,355,927 shares of the company's stock, valued at $37,830,363.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 61,403 shares of company stock valued at $1,582,774 over the last 90 days. 15.40% of the stock is owned by insiders.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers increased its stake in Tyra Biosciences by 12.3% during the second quarter. Rhumbline Advisers now owns 23,572 shares of the company's stock worth $377,000 after purchasing an additional 2,574 shares during the period. Wellington Management Group LLP increased its stake in Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company's stock worth $1,419,000 after purchasing an additional 8,324 shares during the period. SG Americas Securities LLC purchased a new stake in Tyra Biosciences during the third quarter worth about $311,000. Bank of New York Mellon Corp increased its stake in shares of Tyra Biosciences by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company's stock worth $929,000 after buying an additional 14,352 shares during the period. Finally, HighVista Strategies LLC purchased a new stake in shares of Tyra Biosciences during the second quarter worth approximately $257,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.